Onsite production of medical air: is purity a problem?

Abstract Introduction Medical air (MA) is widely used in hospitals, often manufactured onsite by compressing external ambient air and supplied through a local network piping system. Onsite production gives rise to a risk of impurities that are governed by the same pharmacopoeia purity standards appl...

Full description

Bibliographic Details
Main Authors: Paul Edwards, Patricia-Ann Therriault, Ira Katz
Format: Article
Language:English
Published: PAGEPress Publications 2018-05-01
Series:Multidisciplinary Respiratory Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40248-018-0125-8
id doaj-5e50c51674f8455199c36db2159871bb
record_format Article
spelling doaj-5e50c51674f8455199c36db2159871bb2020-11-25T03:03:55ZengPAGEPress PublicationsMultidisciplinary Respiratory Medicine2049-69582018-05-011311310.1186/s40248-018-0125-8Onsite production of medical air: is purity a problem?Paul Edwards0Patricia-Ann Therriault1Ira Katz2VitalAire Canada Inc.VitalAire Canada Inc.Medcial R&D, Air Liquide Santé InternationalAbstract Introduction Medical air (MA) is widely used in hospitals, often manufactured onsite by compressing external ambient air and supplied through a local network piping system. Onsite production gives rise to a risk of impurities that are governed by the same pharmacopoeia purity standards applicable to commercially produced MA. The question to be addressed in this paper is how to assess if a lack of purity poses a medical problem? Methods The MA produced onsite at a major Canadian hospital was monitored for carbon dioxide (CO2) and other impurity gases at high frequency (one per minute) over a two-month period. Results The average CO2 concentration was 255 ppm. The United States Pharmacopeia (USP) threshold of 500 ppm was exceeded during 1% of the total study period, and the average while exceeding the threshold was 526 ppm. The maximum concentration was 634 ppm. Discussion and conclusion To our knowledge, there is only one study that evaluated the effects suffered by respiratory patients of elevated nitric oxide in MA; thus, it is not clear what are the medical bases for the thresholds stated in the USP. To perform a Quality Risk Assessment, the threshold and the time above threshold should be considered in determining the frequency of sampling and analysis, and operating methods required to ensure the quality of MA entering the pipeline meets the clinical, regulatory, and patient safety standards. In conclusion, because the USP does not provide impurity thresholds for specific patients nor time above thresholds, there is a need for the medical community to determine these quantities before it can be known if the purity of MA is a problem.http://link.springer.com/article/10.1186/s40248-018-0125-8Medical airRisk assessmentCarbon dioxide
collection DOAJ
language English
format Article
sources DOAJ
author Paul Edwards
Patricia-Ann Therriault
Ira Katz
spellingShingle Paul Edwards
Patricia-Ann Therriault
Ira Katz
Onsite production of medical air: is purity a problem?
Multidisciplinary Respiratory Medicine
Medical air
Risk assessment
Carbon dioxide
author_facet Paul Edwards
Patricia-Ann Therriault
Ira Katz
author_sort Paul Edwards
title Onsite production of medical air: is purity a problem?
title_short Onsite production of medical air: is purity a problem?
title_full Onsite production of medical air: is purity a problem?
title_fullStr Onsite production of medical air: is purity a problem?
title_full_unstemmed Onsite production of medical air: is purity a problem?
title_sort onsite production of medical air: is purity a problem?
publisher PAGEPress Publications
series Multidisciplinary Respiratory Medicine
issn 2049-6958
publishDate 2018-05-01
description Abstract Introduction Medical air (MA) is widely used in hospitals, often manufactured onsite by compressing external ambient air and supplied through a local network piping system. Onsite production gives rise to a risk of impurities that are governed by the same pharmacopoeia purity standards applicable to commercially produced MA. The question to be addressed in this paper is how to assess if a lack of purity poses a medical problem? Methods The MA produced onsite at a major Canadian hospital was monitored for carbon dioxide (CO2) and other impurity gases at high frequency (one per minute) over a two-month period. Results The average CO2 concentration was 255 ppm. The United States Pharmacopeia (USP) threshold of 500 ppm was exceeded during 1% of the total study period, and the average while exceeding the threshold was 526 ppm. The maximum concentration was 634 ppm. Discussion and conclusion To our knowledge, there is only one study that evaluated the effects suffered by respiratory patients of elevated nitric oxide in MA; thus, it is not clear what are the medical bases for the thresholds stated in the USP. To perform a Quality Risk Assessment, the threshold and the time above threshold should be considered in determining the frequency of sampling and analysis, and operating methods required to ensure the quality of MA entering the pipeline meets the clinical, regulatory, and patient safety standards. In conclusion, because the USP does not provide impurity thresholds for specific patients nor time above thresholds, there is a need for the medical community to determine these quantities before it can be known if the purity of MA is a problem.
topic Medical air
Risk assessment
Carbon dioxide
url http://link.springer.com/article/10.1186/s40248-018-0125-8
work_keys_str_mv AT pauledwards onsiteproductionofmedicalairispurityaproblem
AT patriciaanntherriault onsiteproductionofmedicalairispurityaproblem
AT irakatz onsiteproductionofmedicalairispurityaproblem
_version_ 1724683883029463040